Clinical trials: Anticoagulants
Covid19
Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)
CORONA is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents…
- Trial name
- CORONA (NCT04518735)
- Testing
- Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19
- Where
- Spain
- Volunteers
- 1,707 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Fibrillation, Atrial
Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)
This study was design to investigate the efficacy and safety of NOAC therapy in Koreans
- Trial name
- NOAC (NCT06874894)
- Where
- 2 sites in South Korea
- Volunteers
- 1,021 people
- Sponsor
- Chung-Ang University Hospital
Venous Thromboembolism (VTE), Pulmonary Embolism
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE.
- Conditions
- Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
- Trial name
- NCT02798471
- Testing
- Edoxaban, Standard of Care
- Where
- 140 sites in United States, Argentina and 32 more
- Volunteers
- 290 people
- Sponsor
- Daiichi Sankyo
Adherence to Personalized EBM Anticoagulant Treatment in Patients at High Risk for Stroke
Personalized Evidence-based Medicine in Patients With Atrial Fibrillation
A retrospective analysis
- Trial name
- NCT04774341
- Testing
- anticoagulation treatment
- Where
- Russia
- Volunteers
- 4,200 people
- Sponsor
- Center of Personalized Medicine, Pirogova
Cardiovascular Disease, Atrial Fibrillation
Clinical Decision Support for Stroke Prevention in Atrial Fibrillation
A cluster randomised study in the primary care setting to evaluate a electronic clinical decision tool for stroke prophylaxis in patients with atrial fibrillation.
- Conditions
- Cardiovascular Disease, Atrial Fibrillation, Stroke
- Trial name
- CDS-AF (NCT02635685)
- Testing
- Clinical Decision Support tool
- Where
- Sweden
- Volunteers
- 442,105 people
- Sponsor
- University Hospital, Linkoeping
Rheumatic Heart Disease, Anticoagulant Adverse Reaction
The Clinical Influence of Developing a Sustainable Cardiac Surgery Service to Reduce the Burden of Rheumatic Heart Disease in Sub-Saharan Africa
In this bi-directional program of education, training and research activities based on sustainable development goals aim is to develop cardiac surgery service in Ethiopia.
- Trial name
- RHD-CaSS (NCT04556188)
- Testing
- Cardiac surgery
- Where
- 4 sites in Ethiopia, Norway
- Volunteers
- 200 people
- Sponsor
- Helse Nord-Trøndelag HF
Prothrombin Complex Factor Deficiency
Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal
The purpose of the study is to assess the efficacy and safety of Prothromplex Total as a treatment for the immediate reversal of oral anticoagulant therapy with vitamin K antagonists in patients with acquired deficiency of…
- Trial name
- NCT01159210
- Testing
- Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)
- Where
- 6 sites in Austria, Hungary
- Volunteers
- 61 people
- Sponsor
- Baxalta now part of Shire
Atrial Fibrillation
Non-vitamin K Oral Anticoagulants in Cardioversion
Non-vitamin K oral anticoagulants (NOAC) have been shown to be safe and effective alternatives to warfarin for stroke prevention in patients with nonvalvular AF (NVAF).
- Trial name
- FinCV3 (NCT02911545)
- Volunteers
- 1,000 people
- Sponsor
- Helsinki University Central Hospital
Severe Preeclampsia, Antiphospholipid Syndrome
Antiphospholipid Antibodies and Early Severe Preeclampsia.
The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and…
- Trial name
- NCT01538121
- Where
- Panama
- Volunteers
- 310 people
- Sponsor
- Saint Thomas Hospital, Panama
Healthy
Safety and Dosing Evaluation of REG1 Anticoagulation System
This 1-week study will test the safety and dosing of an anticoagulation system called REG1 that is designed to improve control of "blood thinning." Patients with heart attack and other conditions require treatment with an…
- Trial name
- NCT00113997
- Testing
- REG1
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Deep Vein Thrombosis, Pulmonary Embolism
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of…
- Trial name
- DANNOAC-VTE (NCT03129555)
- Testing
- Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet
- Where
- 26 sites in Denmark
- Volunteers
- 5,000 people
- Sponsor
- Herlev and Gentofte Hospital
Surgery, Oral, Hemorrhage
NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications
Aims: To investigate the incidence of bleeding complications during oral surgical procedures in patients medicated with DOACs. To investigate the perioperative and postoperative bleeding volume during oral surgical procedures in…
- Conditions
- Surgery, Oral, Hemorrhage, Postoperative Complications, Oral Surgical Procedures
- Trial name
- NCT04662515
- Testing
- Type of surgery, Dabigatran, Rivaroxaban
- Where
- 2 sites in Sweden
- Volunteers
- 216 people
- Sponsor
- Malmö University
Heart Failure, Cardiogenic Shock
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to: 1.
- Conditions
- Heart Failure, Cardiogenic Shock, Congenital Heart Disease, Cardiomyopathies
- Trial name
- TROLLEY (NCT06080074)
- Testing
- Cardiohelp device (VA-ECMO), Heparin, Bivalirudin
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Cardiology
Bivalirudin as a Procedural Anticoagulant in Pediatrics
Pharmacokinetics and safety of weight based bivalirudin in children
- Trial name
- NCT00503126
- Testing
- bivalirudin
- Volunteers
- 110 people
- Sponsor
- The Medicines Company
Cardiac Disease
Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
A committee will judge the safety and effectiveness of edoxaban and the regular treatment (standard of care). All children in the study will receive free treatment.
- Trial name
- NCT03395639
- Testing
- Edoxaban, Standard of Care (SOC)
- Where
- 48 sites in United States, Austria and 12 more
- Volunteers
- 168 people
- Sponsor
- Daiichi Sankyo
Idiopathic Intracranial Hypertension
Quantitative D-dimer Level and Anticoagulant Therapy in Idiopathic Intracranial Hypertension
Idiopathic intracranial hypertension (IIH) is a syndrome characterized by elevated intracranial pressure (ICP) of unknown etiology.
- Trial name
- NCT03963336
- Testing
- LMWH, acetazolamide
- Where
- Egypt
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Fayoum University
Venous Thromboembolism
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
The aim of the study is to investigate the safety and tolerability of dabigatran etexilate solution in children aged less than 1 year, to demonstrate comparable PK/PD relationship to older children and adults and to confirm…
- Trial name
- NCT02223260
- Testing
- dabigatran
- Where
- 4 sites in Canada, France and 1 more
- Volunteers
- 8 people
- Sponsor
- Boehringer Ingelheim
Thrombosis, Nadroparin
Nadroparin Pharmacokinetics in Different Stages of COVID-19
Objective: The risk of thrombotic complications in critical COVID-19 patients remains extremely high, and multicenter trials failed to prove the survival benefit of escalated doses of low molecular weight heparins (LMWH) in this…
- Conditions
- Thrombosis, Nadroparin, COVID-19, Mechanical Ventilation
- Trial name
- NCT05621915
- Testing
- Nadroparin
- Where
- Poland
- Volunteers
- 43 people
- Sponsor
- Medical University of Lublin
Anticoagulant-induced Bleeding, Direct Oral Anticoagulant
Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation Pilot Study
The peri-procedural management of direct oral anticoagulants (DOACs) in persons with cancer (PWC) undergoing tunneled or port central venous catheter (CVC) insertion is a common but understudied clinical problem, with conflicting…
- Conditions
- Anticoagulant-induced Bleeding, Direct Oral Anticoagulant, Cancer, Central Venous Catheter
- Trial name
- VENO CAT (NCT06887270)
- Testing
- Continued DOAC, Interrupted DOAC
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Anticoagulants
Epidemiological Description of Health Determinants in Italian Anticoagulated Population
The primary aim of this study is to describe and develop a cross-sectional profile of the level of the main health determinants in the Italian anticoagulated population (disease knowledge; self-efficacy; health literacy; quality…
- Trial name
- EDIA (NCT05710562)
- Testing
- Name not applicable
- Where
- Italy
- Volunteers
- 468 people, healthy volunteers welcome
- Sponsor
- IRCCS Policlinico S. Donato